Recent research indicates that the rate of global warming caused by human activity is at an all-time high.* In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.
This year, Pioneer is accelerating the development of planetary health innovations through a comprehensive programme of events, a “Golden Ticket” competition, venture development support, specialist lab space, and access to its expert network.
“With global temperatures on the rise, supporting innovations…
Sandwich, Kent, UK / 24 September 2024 / A group of former Pfizer employees have successfully created their own businesses based at and supported by Discovery Park, a thriving life sciences community in Kent. The new businesses are all contract research organisations, namely Biowaived, Matheus Engineering and Particology Ltd. Their launch has been supported by Pfizer’s Pharmaceutical Sciences Small Molecule (PSSM) division, with contracts for work to build their initial viability and momentum. The opportunity to establish these new businesses emerged from Pfizer’s cost realignment…
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has today announced the first cohort of awardees of its Collaborative Discovery Programme (CDP) funding.
The £3 million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections in people with CF.
CF affects over 162,000 people globally. People with CF are affected by life-threatening lung infections that can permanently change lung function and reduce their quality of life. Growing resistance to antimicrobials and lack of effective…
Laurence Reid joins as Chairman, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Third Rock Ventures
Brad Crutchfield appointed as Non-Executive Director, previously 10x Genomics, QIAGEN, Illumina, and Bio-Rad Laboratories
Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of…
Cambridge, UK – September 20th 2024 - The Cambridge Crystallographic Data Centre (CCDC) is pleased to announce the integration of our industry-validated Genetic Optimization for Ligand Docking (GOLD) software with Cadence Molecular Sciences (OpenEye)’s Orion platform. This collaboration provides computational and medicinal chemists with a powerful new toolset to streamline and enhance their protein–ligand docking workflows on Cadence Molecular Sciences cloud-native Orion platform, a crucial step in pharmaceutical development.
GOLD Protein–Ligand Docking Software: A Benchmark…
Discovery Spark is a transformative innovation growth programme for early-stage companies, packed with invaluable resources and support. Across a number of in-person sessions led by seasoned professionals and industry leaders, participants will gain the essential skills needed to lay robust foundations in their business and prepare for investment. Discovery Spark is aimed at businesses across a diverse range of sectors including biotech, medtech, diagnostics and advanced therapies and those who have raised up to £1 million in equity. The programme plays a pivotal role in helping founders take…
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform
Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management
Cambridge, UK, 10 September 2024: PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors,…
Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind
Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform
Novel “nanosyringe” platform can deliver complex biologic payloads selectively and intracellularly, unlocking the interior of the cell for new intervention possibilities in unmet medical needs
Coventry, UK, 10 September 2024: NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform…
Pioneer Group, a specialist in life science infrastructure and venture building, has
teamed up with global healthcare company Novo Nordisk to launch a Golden
Ticket designed to help accelerate innovations in cardiometabolic diseases, rare
blood and rare endocrine disorders.
The Golden Ticket programme is aimed at early-stage biotech companies focused
on novel drug targets and transformational medicines in cardiometabolic disease,
with robust research plans and potential for successful research development.
Pioneer Group and Novo Nordisk want to hear from science and technology
founders as…
AMSBIO offers a production service for high quality custom transduction-ready viral particles designed to support your research and save you valuable time.
Drawing upon extensive knowledge in research areas including Adeno Associated Virus, Adenovirus, Herpes Simplex Virus, Lentivirus, MMLV Retrovirus and more - AMSBIO viral services include the design and construction of the vectors, ultimately providing you with high quality viral particles that you can rely on.
Maja Petkovic, AMSBIO business unit manager commented “Recently we supplied a custom lentiviral vector to…